DR
David Risinger Leerink Partners Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
26
Pfizer
PFE
$140B
| $24.71 | $48 |
94%
upside
| Market Perform |
1 Feb ‘23
2 years ago |
|
27
Johnson & Johnson
JNJ
$429B
| $176.96 | $186 |
5%
upside
| Outperform |
20 Jan ‘23
2 years ago |
|
28
Roivant Sciences
ROIV
$8.82B
| $13.48 | $10 |
26%
downside
| Outperform |
19 Dec ‘22
2 years ago |
|
29
Eli Lilly
LLY
$662B
| $750.61 | $410 |
45%
downside
| Outperform |
16 Dec ‘22
2 years ago |
|
30
Vaxcyte
PCVX
$4.21B
| $32.72 | $60 |
83%
upside
| Outperform |
16 Dec ‘22
2 years ago |
|
31
Theravance Biopharma
TBPH
$701M
| $13.76 | $14 |
2%
upside
| Outperform |
17 Nov ‘22
2 years ago |
|
32
HilleVax
HLVX
$105M
| $2.10 | $30 |
1,329%
upside
| Outperform |
24 May ‘22
3 years ago |
|
33
Organon & Co
OGN
$2.72B
| $10.37 | $37 |
257%
upside
| Equal-Weight |
22 Feb ‘22
3 years ago |
|
|
34
Eli Lilly
LLY
$662B
| $750.61 | $265 |
65%
downside
| Overweight |
4 Feb ‘22
3 years ago |
|
|
35
Pfizer
PFE
$140B
| $24.71 | $42 |
70%
upside
| Equal-Weight |
10 May ‘21
4 years ago |
|
36
Bristol-Myers Squibb
BMY
$95.1B
| $47.23 | $62 |
31%
upside
| Equal-Weight |
30 Apr ‘21
4 years ago |
|
37
Jazz Pharmaceuticals
JAZZ
$7.88B
| $128.53 | $176 |
37%
upside
| Equal-Weight |
1 Apr ‘21
4 years ago |
|
38
Viatris
VTRS
$12.2B
| $10.45 | $16 |
53%
upside
| Equal-Weight |
10 Mar ‘21
4 years ago |
|
39
Perrigo
PRGO
$3.07B
| $22.28 | $45 |
102%
upside
| Equal-Weight |
5 Mar ‘21
4 years ago |
|
40
Bausch Health
BHC
$2.71B
| $7.21 | $35 |
385%
upside
| Equal-Weight |
26 Feb ‘21
4 years ago |
|
41
AbbVie
ABBV
$371B
| $210.42 | $116 |
45%
downside
| Overweight |
28 Jan ‘21
4 years ago |
|
42
Elanco Animal Health
ELAN
$9.46B
| $18.76 | $41 |
119%
upside
| Overweight |
24 Nov ‘20
4 years ago |
|
43
Zoetis
ZTS
$67.3B
| $149.79 | $174 |
16%
upside
| Equal-Weight |
13 Nov ‘20
4 years ago |
|
44
Royalty Pharma
RPRX
$15.5B
| $36.50 | $51 |
40%
upside
| Equal-Weight |
13 Jul ‘20
5 years ago |
|
45
Teva Pharmaceuticals
TEVA
$22.1B
| $19.68 | $8 |
59%
downside
| Underweight |
2 Apr ‘20
5 years ago |
|
46
Merck
MRK
$210B
| $84.61 | $89 |
5%
upside
| Overweight |
2 Apr ‘20
5 years ago |
|
47
Amneal Pharmaceuticals
AMRX
$3.06B
| $9.89 | $3 |
70%
downside
| Equal-Weight |
2 Apr ‘20
5 years ago |
|
48
Alkermes
ALKS
$4.7B
| $27.85 | $16 |
43%
downside
| Equal-Weight |
2 Apr ‘20
5 years ago |
|
|
49
Bristol-Myers Squibb
BMY
$95.1B
| $47.23 | $75 |
59%
upside
| Buy |
1 Apr ‘20
5 years ago |
|